Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/129861
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saez Perdomo, María Nieves | en_US |
dc.contributor.author | Stuckey, Ruth | en_US |
dc.contributor.author | González-Pérez, Elena | en_US |
dc.contributor.author | Sánchez-Sosa, Santiago | en_US |
dc.contributor.author | Estupiñan-Cabrera, Paula | en_US |
dc.contributor.author | Lakhwani Lakhwani, Sunil | en_US |
dc.contributor.author | González San Miguel, José David | en_US |
dc.contributor.author | Hernanz Soler, Nuria | en_US |
dc.contributor.author | Gordillo, Marina | en_US |
dc.contributor.author | González Brito, Gloria | en_US |
dc.contributor.author | Tapia-Torres, María | en_US |
dc.contributor.author | Ruano, Ana | en_US |
dc.contributor.author | Segura Díaz, Adrian | en_US |
dc.contributor.author | Luzardo, Hugo | en_US |
dc.contributor.author | Bilbao Sieyro, Cristina | en_US |
dc.contributor.author | Gómez Casares, María Teresa | en_US |
dc.date.accessioned | 2024-04-15T11:08:54Z | - |
dc.date.available | 2024-04-15T11:08:54Z | - |
dc.date.issued | 2024 | en_US |
dc.identifier.issn | 2038-8322 | en_US |
dc.identifier.other | Scopus | - |
dc.identifier.other | WoS | - |
dc.identifier.uri | http://hdl.handle.net/10553/129861 | - |
dc.description.abstract | Background: Second- and third-generation tyrosine kinase inhibitors (TKIs) are now available to treat chronic-phase chronic myeloid leukemia (CP-CML) in the first and second line. However, vascular adverse events (VAEs) have been reported for patients with CML treated with some TKIs. Methods: We retrospectively evaluated the cumulative incidence (CI) and cardiovascular risk for 210 patients included in the Canarian Registry of CML. Result: With a mean follow up of 6 years, 19/210 (9.1%) patients developed VAEs, all of whom presented at least one cardiovascular risk factor at diagnosis. The mean time to VAE presentation was 54 months from the start of TKI treatment. We found a statistically significant difference between the CI for nilotinib-naïve vs. nilotinib-treated patients (p = 0.005), between dasatinib-naïve and dasatinib-treated patients (p = 0.039), and for patients who received three lines of treatment with first-line imatinib vs. first-line imatinib (p < 0.001). From the multivariable logistic regression analyses, the Framingham risk score (FRS) and patients with three lines of TKI with first-line imatinib were the only variables with statistically significant hazard ratios for VAE development. Significant increases in HDL-C and total cholesterol may also be predictive for VAE. Conclusions: In conclusion, it is important to estimate the cardiovascular risk at the diagnosis of CML as it can help determine whether a patient is likely to develop a VAE during TKI treatment. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Hematology Reports | en_US |
dc.source | Hematology Reports [ISSN 2038-8322], v. 16 (1), p. 140-150, (Marzo 2024). | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320708 Hematología | en_US |
dc.subject | 320713 Oncología | en_US |
dc.subject.other | Adverse Event | en_US |
dc.subject.other | Cardiovascular | en_US |
dc.subject.other | Chronic Myeloid Leukemia | en_US |
dc.subject.other | Imatinib | en_US |
dc.subject.other | Lipid Metabolism | en_US |
dc.subject.other | Nilotinib | en_US |
dc.subject.other | Tyrosine Kinase Inhibitor (Tki) | en_US |
dc.title | The cardiovascular event risk associated with Tyrosine Kinase Inhibitors and the lipid rrofile in patients with chronic myeloid leukemia | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3390/hematolrep16010015 | en_US |
dc.identifier.scopus | 85188843991 | - |
dc.identifier.isi | 001193547800001 | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | 0000-0001-6955-2290 | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.authorscopusid | 57202726436 | - |
dc.contributor.authorscopusid | 8940351300 | - |
dc.contributor.authorscopusid | 57216530339 | - |
dc.contributor.authorscopusid | 57216528499 | - |
dc.contributor.authorscopusid | 58958089500 | - |
dc.contributor.authorscopusid | 57299516300 | - |
dc.contributor.authorscopusid | 6603074735 | - |
dc.contributor.authorscopusid | 58958242100 | - |
dc.contributor.authorscopusid | 58958242200 | - |
dc.contributor.authorscopusid | 6602474897 | - |
dc.contributor.authorscopusid | 15064829000 | - |
dc.contributor.authorscopusid | 58958242300 | - |
dc.contributor.authorscopusid | 57216532422 | - |
dc.contributor.authorscopusid | 55022691900 | - |
dc.contributor.authorscopusid | 57550315900 | - |
dc.contributor.authorscopusid | 6602513846 | - |
dc.identifier.eissn | 2038-8330 | - |
dc.description.lastpage | 150 | en_US |
dc.identifier.issue | 1 | - |
dc.description.firstpage | 140 | en_US |
dc.relation.volume | 16 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | 26823283 | - |
dc.contributor.daisngid | 616098 | - |
dc.contributor.daisngid | 8184055 | - |
dc.contributor.daisngid | 49833414 | - |
dc.contributor.daisngid | 56500234 | - |
dc.contributor.daisngid | 10592718 | - |
dc.contributor.daisngid | 40658592 | - |
dc.contributor.daisngid | 14365508 | - |
dc.contributor.daisngid | 8308301 | - |
dc.contributor.daisngid | 56636491 | - |
dc.contributor.daisngid | 30635072 | - |
dc.contributor.daisngid | 28725962 | - |
dc.contributor.daisngid | 13982043 | - |
dc.contributor.daisngid | 53430441 | - |
dc.contributor.daisngid | 54769301 | - |
dc.contributor.daisngid | 50134566 | - |
dc.description.numberofpages | 11 | en_US |
dc.utils.revision | Sí | en_US |
dc.contributor.wosstandard | WOS:Perdomo, MNS | - |
dc.contributor.wosstandard | WOS:Stuckey, R | - |
dc.contributor.wosstandard | WOS:González-Pérez, E | - |
dc.contributor.wosstandard | WOS:Sánchez-Sosa, S | - |
dc.contributor.wosstandard | WOS:Estupiñan-Cabrera, P | - |
dc.contributor.wosstandard | WOS:Lakhwani, SL | - |
dc.contributor.wosstandard | WOS:San Miguel, JDG | - |
dc.contributor.wosstandard | WOS:Soler, NH | - |
dc.contributor.wosstandard | WOS:Gordillo, M | - |
dc.contributor.wosstandard | WOS:Brito, GG | - |
dc.contributor.wosstandard | WOS:Tapia-Torres, M | - |
dc.contributor.wosstandard | WOS:Ruano, A | - |
dc.contributor.wosstandard | WOS:Segura-Díaz, A | - |
dc.contributor.wosstandard | WOS:Luzardo, H | - |
dc.contributor.wosstandard | WOS:Bilbao-Sieyro, C | - |
dc.contributor.wosstandard | WOS:Gómez-Casares, MT | - |
dc.date.coverdate | Marzo 2024 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 0,263 | - |
dc.description.sjrq | Q4 | - |
dc.description.esci | ESCI | - |
dc.description.miaricds | 9,6 | - |
item.fulltext | Con texto completo | - |
item.grantfulltext | open | - |
crisitem.author.dept | Departamento de Morfología | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-4796-1445 | - |
crisitem.author.orcid | 0000-0003-0505-5126 | - |
crisitem.author.fullName | Segura Díaz, Adrian | - |
crisitem.author.fullName | Bilbao Sieyro, Cristina | - |
crisitem.author.fullName | Gómez Casares, María Teresa | - |
Appears in Collections: | Artículos |
Page view(s)
46
checked on Aug 31, 2024
Download(s)
12
checked on Aug 31, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.